Premium
Mobilization of hematopoietic progenitor stem cells in allogeneic setting with lenograstim by subcutaneous injection, in daily or twice‐daily dosing: a single‐center prospective study with historical control
Author(s) -
Martino Massimo,
Moscato Tiziana,
Barillà Santina,
Dattola Antonia,
Pontari Antonella,
Fedele Roberta,
Furlò Giuseppe,
Marzia Stilo Carmen,
Alberto Gallo Giuseppe,
Tripepi Giovanni
Publication year - 2015
Publication title -
transfusion
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.045
H-Index - 132
eISSN - 1537-2995
pISSN - 0041-1132
DOI - 10.1111/trf.13117
Subject(s) - medicine , granulocyte colony stimulating factor , cd34 , progenitor cell , apheresis , dosing , haematopoiesis , hematopoietic stem cell transplantation , gastroenterology , surgery , transplantation , stem cell , urology , chemotherapy , biology , platelet , genetics
BACKGROUND Although the mobilization of hematopoietic progenitor stem cells from healthy donors (HDs) using granulocyte–colony‐stimulating factor is widely used, the ideal method for the administration of the cytokine has not yet been determined. STUDY DESIGN AND METHODS Seventy‐five consecutive HDs received lenograstim (LENO) as mobilization agent. LENO was given subcutaneously at a dose of 10 µg/kg in a once‐daily dose (ODD) every 24 hours. Results were compared with a historical control group of 181 HDs treated with 5 µg/kg LENO twice‐daily dose (TDD) with a time interval of 12 hours. RESULTS CD34+ cell concentrations evaluated on Day 4 and on Day 5 were 45 × 10 6 (range, 6 × 10 6 ‐217 × 10 6 )/L and 75 × 10 6 (range, 7 × 10 6 ‐279 × 10 6 )/L with ODD versus 36 × 10 6 (range, 3 × 10 6 ‐200 × 10 6 )/L and 55 × 10 6 (range, 3 × 10 6 ‐738 × 10 6 )/L with TDD (p = 0.067 and p = 0.001). The collected CD34+ cell counts in first apheresis procedure were 5.6 × 10 6 ± 2.9 × 10 6 and 5.7 × 10 6 ± 3 × 10 6 /kg donor and recipient body weight in the ODD versus 5.4 × 10 6 ± 3.8 × 10 6 and 5.3 × 10 6 ± 3.5 × 10 6 /kg in the TDD cohort, respectively (p = 0.08 and p = 0.02). Five HDs (6.7%) mobilized CD34+ cells of fewer than 2 × 10 6 /kg recipient body weight in the ODD group compared with seven HDs (3.9%) in the TDD group (p = 0.3). CONCLUSIONS Once‐daily administration of LENO is at least as effective as twice‐daily administration for the mobilization of CD34+ cells in HDs.